A decision by Qantas to outsource its ground staff was not timed to head off industrial action by the Transport Workers’ Union, the Full Federal Court has heard as the airline seeks to overturn a finding that it engaged in adverse action when it terminated around 1,800 employees last year.
Logistics company GetSwift will argue on appeal that a judge who found the company took a “PR-driven approach” to ASX statements was wrong in his assessment of whether those statements contained material omissions.
Australia’s largest law firm MinterEllison has announced the election of leading mergers and acquisitions and government practice lawyer Andrew Rentoul to the position of chairman.
Former legal representatives of companies in the Mayfair 101 group are considering an application to strike out part of an appeal that alleges their “flagrant incompetence” led to director James Mawhinney copping a 20-year ban on soliciting investor funds.
Johnson Winter & Slattery has snagged two tax bigwigs from Deloitte and KPMG Law to meet growing client demand for tax advice from law firms.
The High Court has shot down Greensill founder Lex Greensill’s bid for special leave to challenge a finding that he owes tax on $58 million in capital gains, including income from the sale of shares in the collapsed UK-based supply chain finance company.
A Credit Suisse supply chain fund that was left heavily exposed with the collapse of Greensill Capital alleges Insurance Australia Group owes $43 million under a policy indemnifying it for outstanding debt owed by the failed financing firm.
A court has shut down action by the CFMEU on behalf of coal miners who were rostered to work Christmas Day and Boxing Day at the Daunia Mine in central Queensland in 2019.
The brother of Liberal Senator and former resources minister Matt Canavan can investigate potential claims against Glencore in his long running legal spat over the Rolleston coal mine, after a court greenlit his bid for the appointment of special purpose liquidators.
A second class action investigation against regenerative medicine company Mesoblast is underway, this one looking at claim it misled shareholders about the potential application of a developmental stem cell product to treat terminally-ill children.